Drug Trial Radar · NCT07388511
A Study of Elenestinib in Healthy Adult Female Participants
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 5, 2026
Primary completion
Apr 2, 2026
Study completion Apr 2, 2026
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.
Conditions
- Healthy Participants
Interventions
ElenestinibDrug
Specified dose on specified days
MidazolamDrug
Specified dose on specified days
Levonorgestrel/Ethinyl EstradiolDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)Time frame: Up to 27 days
- Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)Time frame: Up to 27 days
- Percent of AUC0-inf extrapolated (AUC%extrap)Time frame: Up to 27 days
- Maximum observed concentration (Cmax)Time frame: Up to 27 days
- Time to reach Cmax (Tmax)Time frame: Up to 27 days
- Apparent first-order terminal elimination half-life (t1/2)Time frame: Up to 27 days
- Apparent total plasma clearance after oral administration (CL/F)Time frame: Up to 27 days
- Apparent volume of distribution during the terminal elimination phase after oral administration (Vz/F)Time frame: Up to 27 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.